



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Efungumab

Cat. No.:	HY-P9962
CAS No.:	762260-74-2
Target:	Fungal
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC) ^[1] .								
In Vivo	<p>Efungumab (2 mg/kg, i.p., daily for 3 days) significantly decreases mean organ colony counts and increases negative liver biopsies for many of the isolates in CD1 mice models of disseminated <i>c. albicans</i> disease^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>CD1 mice models of disseminated <i>c. albicans</i> disease^[2]</td></tr><tr><td>Dosage:</td><td>2 mg/kg, daily for 3 days</td></tr><tr><td>Administration:</td><td>Intraperitoneal injection (i.p.)</td></tr><tr><td>Result:</td><td>Decreased mean organ colony counts and increased negative liver biopsies for many of the isolates.</td></tr></table>	Animal Model:	CD1 mice models of disseminated <i>c. albicans</i> disease ^[2]	Dosage:	2 mg/kg, daily for 3 days	Administration:	Intraperitoneal injection (i.p.)	Result:	Decreased mean organ colony counts and increased negative liver biopsies for many of the isolates.
Animal Model:	CD1 mice models of disseminated <i>c. albicans</i> disease ^[2]								
Dosage:	2 mg/kg, daily for 3 days								
Administration:	Intraperitoneal injection (i.p.)								
Result:	Decreased mean organ colony counts and increased negative liver biopsies for many of the isolates.								

REFERENCES

[1]. Karwa R, et al. Efungumab: a novel agent in the treatment of invasive candidiasis. *Ann Pharmacother.* 2009 Nov;43(11):1818-23.

[2]. Cowen LE, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. *Proc Natl Acad Sci U S A.* 2009 Feb 24;106(8):2818-23.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA